Moderna plans to build a state-of-the-art mRNA facility in Africa with the goal of producing up to 500 million doses of vaccines each year, the company said in a news release.
Moderna anticipates investing up to $500 million in this new facility, which is expected to include drug substance manufacturing with the opportunity for fill/finish and packaging capabilities at the site. The company said it expects to begin a process for country and site selection soon.
Moderna said its pipeline “includes 20 vaccine candidates in its prophylactic vaccines modality, including vaccines against respiratory viruses, vaccines against latent viruses, and vaccines against threats to global public health.”
According to The Washington Post, the Biden Administration “has been pressuring Moderna for months to increase its output and send doses to lower-income countries.”
